STOCKHOLM, Aug. 22, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the positive results from the pharmacokinetic (PK) study with cobitolimod in patients with moderate to severe ulcerative colitis will be presented at one of the leading gastroenterology conferences, the United European Gastroenterology Week (UEGW). The abstract was selected as one of the best abstracts for poster presentation and is therefore also chosen to be presented orally in one of the moderated poster sessions.
"We are very pleased that our presentation of the PK study results was selected as one of the best abstracts for poster presentation at UEGW, one of the largest gastroenterology congresses in the world," said Jenny Sundqvist, CEO of InDex Pharmaceuticals. "This shows that there is a great interest from the medical community in our results."
The PK study results will be presented by principal investigator Professor Per Hellström on October 15 at 10:30 CET on Poster Stage 1, during the moderated poster session: "Medical therapy of IBD: Facts and challenges."
Results from the PK study included PK data from 7 patients with moderate to severe ulcerative colitis treated with doses of 500 mg of cobitolimod administered rectally. The systemic uptake of cobitolimod was limited both for patients with active disease and in clinical remission, with the majority of patients having undetectable levels of cobitolimod in the plasma after 8 hours. Even though it was a small-scale open-label study, it was encouraging that 4 out of 7 patients achieved clinical remission at week 6 after receiving two doses of 500 mg cobitolimod. In line with previous studies, cobitolimod was well tolerated and no serious adverse events were reported in the study.
During UEGW, taking place in Copenhagen 14th -17th of October, InDex Pharmaceuticals will also be present at booth C3-84 in the exhibition hall at the Bella Center. InDex's team members will be available on site to provide information about cobitolimod and the ongoing phase III program CONCLUDE.
For more information:
Jenny Sundqvist, CEO
Phone: +46 8 122 038 50
E-mail: jenny.sundqvist@indexpharma.com
Johan Giléus, deputy CEO and CFO
Phone: +46 8 122 038 50
E-mail: johan.gileus@indexpharma.com
Publication
The information was submitted for publication through the agency of the contact person set out above at 09:30 CET on August 22, 2023.
This is an English translation of the Swedish press release. In case of discrepancies between the English translation and the Swedish press release, the Swedish press release shall prevail.
InDex Pharmaceuticals in brief
InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The company's lead asset is the drug candidate cobitolimod, which is being evaluated in the phase III program CONCLUDE as a novel treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammation of the large intestine. InDex has also developed a platform of patent protected discovery stage substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in the treatment of various immunological diseases.
InDex is based in Stockholm, Sweden. The company's shares (ticker INDEX) are traded on Nasdaq First North Growth Market Stockholm. Redeye AB is the company's Certified Adviser. For more information, please visit www.indexpharma.com.
Information in this press release is intended for investors.
The following files are available for download:
https://mb.cision.com/Main/9612/3821195/2240079.pdf | Results from PK study with cobitolimod to be presented at UEGW |
View original content:https://www.prnewswire.co.uk/news-releases/positive-results-from-pk-study-with-cobitolimod-selected-as-one-of-the-best-abstracts-for-poster-presentation-at-uegw-index-pharmaceuticals-301906514.html
